O ver the past two to three decades, pelvic ultrasonography and measurement of the serum concentration of human chorionic gonadotropin (hCG) ( Table 1 ) have become mainstays in the diagnosis and management of early-pregnancy problems. These tests, which allow earlier detection of pregnancy and more accurate diagnosis of its complications than were previously possible, have revolutionized the management of intrauterine pregnancies and markedly reduced the morbidity and mortality associated with ectopic pregnancy. 1, 2 Although these tests have indisputable benefits, their misuse and misinterpretation can lead to interventions that inadvertently damage pregnancies that might have had normal outcomes. 3, 4 There are well-documented instances of women with intrauterine pregnancies treated with intramuscular methotrexate for suspected ectopic pregnancy, leading to failure of the pregnancy ("miscarriage") or the birth of a malformed baby. 5 Furthermore, considerable evidence suggests that mistakes such as these are far from rare. Malpractice lawsuits related to this type of error constitute "a rapidly increasing source of medical liability actions," 6 and there are online support groups for women erroneously treated in this manner. 7 When a woman presents with symptoms of pain or bleeding in early pregnancy, the main diagnostic possibilities are a currently viable intrauterine pregnancy, a failed (or failing) intrauterine pregnancy, and ectopic pregnancy. Serum hCG measurement and pelvic ultrasonography are commonly performed to aid in the differential diagnosis. At that point, unless a life-threatening situation dictates immediate management, a key question is: "Is there a chance of a viable pregnancy?" (Table 1 ). This question is central to management decision making in two main clinical contexts: intrauterine pregnancy of uncertain viability and pregnancy of unknown location (Table 1) . For a woman with an intrauterine pregnancy of uncertain viability, the answer to this question is central in deciding whether to evacuate the uterus. For a woman with a pregnancy of unknown location, the answer plays an important role in deciding whether to initiate treatment for a suspected ectopic pregnancy.
A pregnancy is diagnosed as nonviable if it meets one of the commonly accepted positivity criteria for that diagnosis, such as the embryonic size at which nonvisualization of a heartbeat on ultrasonography is diagnostic of failed pregnancy. The positivity criterion for any diagnostic test should depend, in part, on the downstream consequences of false positive and false negative diagnoses. 8 In diagnosing nonviability of an early pregnancy, a false positive diagnosis -erroneously diagnosing nonviability -carries much worse consequences than a false negative diagnosis -failing to diagnose a pregnancy as nonviable. For either an intrauterine pregnancy of uncertain viability or a pregnancy of unknown location, the consequence of a false positive diagnosis of nonviability may be dire: medical or surgical intervention that eliminates or severely damages a viable pregnancy. This is much worse than the consequence of a false negative diagnosis in women with an intrauterine pregnancy of uncertain viability: a delay (usually by a few days) in intervention for a failed pregnancy. Likewise, for a pregnancy of unknown location, harming a potentially normal intrauterine pregnancy is considerably worse than the possible consequence of a false negative diagnosis: a short delay in treatment of an ectopic pregnancy in a woman who is being followed medically and has no ultrasonographically identifiable adnexal mass.
Thus, the criteria for diagnosing nonviability in early pregnancy should virtually eliminate false positive results. That is, the goal is a specificity of 100%, which yields a positive predictive value of 100% for nonviability, regardless of the prior probability of that diagnosis. We recognize that this goal cannot always be achieved in clinical practice because of the dependence of ultra sonography on the expertise of the operator and because of statistical limitations in ruling out very rare events. However, we are confident that current data allow us to achieve a specificity extremely close to 100%. Although it would be ideal to have both high sensitivity and high specificity, diagnosis of early pregnancy failure requires a focus on the latter at the expense of the former. 4, 9 Research in the past 2 to 3 years 10-12 has shown that previously accepted criteria for ruling out a viable pregnancy, which were based on small numbers of patients, 9 are not stringent enough to avoid false positive test results. Dissemination of this new information to practitioners and the achievement of standardized practice protocols are challenging, because the diagnosis and management of early-pregnancy complications involve physicians from multiple specialties, including radiology, obstetrics and gynecology, emergency medicine, and family medicine. As a result, there 
Intrauterine pregnancy of uncertain viability
A woman is considered to have an intrauterine pregnancy of uncertain viability if transvaginal ultrasonography shows an intrauterine gestational sac with no embryonic heartbeat (and no findings of definite pregnancy failure).*
Pregnancy of unknown location
A woman is considered to have a pregnancy of unknown location if she has a positive urine or serum pregnancy test and no intrauterine or ectopic preg nancy is seen on transvaginal ultrasonography.
Diagnostic tests
Human chorionic gonadotropin * In a woman with a positive urine or serum pregnancy test, an intrauterine fluid collection with rounded edges contain ing no yolk sac or embryo is most likely a gestational sac; it is certain to be a gestational sac if it contains a yolk sac or embryo. † Transabdominal imaging without transvaginal scanning may be sufficient for diagnosing early pregnancy failure when an embryo whose crown-rump length is 15 mm or more has no visible cardiac activity.
is a patchwork of sometimes conflicting, often outdated published recommendations and guidelines from professional societies. 13 In this review, we examine the diagnosis of nonviability in early intrauterine pregnancy of uncertain viability and in early pregnancy of unknown location separately, focusing mainly on the initial (or only) ultrasonographic study performed during the pregnancy. Our recommendations are meant to apply to any practice, subspecialty or community-based, that meets at least the minimum quality criteria for pelvic ultrasonography listed in Table 1 .
Di agnosing Pr egna nc y Fa ilur e in a n In t r au ter ine Pr egna nc y of Uncer ta in V i a bil i t y
The sequence of events in early pregnancy, as seen on transvaginal ultrasonography, follows a fairly predictable pattern. The gestational sac is first seen at approximately 5 weeks of gestational age, 14, 15 appearing as a small cystic-fluid collection with rounded edges and no visible contents, located in the central echogenic portion of the uter us (i.e., within the decidua). Previously described ultrasonographic signs of early pregnancy -the "double sac sign" 16 and "intradecidual sign" 17 -were defined with the use of transabdominal ultrasonography, but with current transvaginal ultrasono graphic technology, these signs are absent in at least 35% of gestational sacs. 18 Therefore, any round or oval fluid collection in a woman with a positive pregnancy test most likely represents an intrauterine gestational sac ( Fig. 1 ) 19, 20 and should be reported as such; it is much less likely to be a pseudogestational sac or decidual cyst, findings that can be present in a woman with an ectopic pregnancy. 21, 22 The yolk sac, a circular structure about 3 to 5 mm in diameter, makes its appearance at about 5 1 ∕2 weeks of gestation. The embryo is first seen adjacent to the yolk sac at about 6 weeks, at which time the heartbeat is present as a flickering motion. 14, 15 Variations from the expected pattern of development are worrisome or, if major, definitive for early pregnancy failure. The criteria most often used to diagnose pregnancy failure are the absence of cardiac activity by the time the embryo has reached a certain length (crown-rump length), the absence of a visible embryo by the time the gestational sac has grown to a certain size (mean sac diameter), and the absence of a visible embryo by a certain point in time.
Crown-Rump Length as a Criterion for Failed Pregnancy
Shortly after transvaginal ultrasonography became widely available in the mid-to-late 1980s, several studies sought to determine the cutoff value for crown-rump length above which cardiac activity is consistently visible on transvaginal ultrasonography in a viable pregnancy. The cutoff values identified in these studies were 4 mm 23,24 and 5 mm. 25, 26 Despite the small number of patients in these studies, a crown-rump length of 5 mm was widely recommended as a positivity criterion for diagnosing failed pregnancy when no cardiac activity is seen. [27] [28] [29] [30] [31] Although the raw data from some of these studies suggest that a 5-mm cutoff for crownrump length has a specificity of 100% and a sensitivity of approximately 50%, a systematic review of the literature concluded that, because of the small numbers of patients, the 95% confidence interval for specificity was fairly wide: 90 to 100%. 9 This indicates that there is a substantial likelihood that a 5-mm cutoff can result in a false positive diagnosis of pregnancy failure. It is therefore not surprising that recent studies involving many more patients have described several embryos with a crown-rump length of 5 to 6 mm and no cardiac activity that subsequently proved to be viable. 10, 11 It has also been shown that the interobserver variation in the measurement of crown-rump length is ±15%. 32 Thus, a crown-rump length of 6 mm (the upper limit above) as measured by one practitioner may be 15% greater, or 6.9 mm, when measured by another practitioner.
These recent studies suggest that it is prudent to use a cutoff of 7 mm (rather than 5 mm) for crown-rump length with no cardiac activity (Table  2) for diagnosing failed pregnancy ( Fig. 2A) . This would yield a specificity and positive predictive value of 100% (or as close to 100% as can be determined). Because cardiac activity is usually visible as soon as an embryo is detectable, the finding of no heartbeat with a crown-rump length of less than 7 mm is suspicious for, though not diagnostic of, failed pregnancy (see video and Fig. S1 in the Supplementary Appendix, both available with the full text of this article at NEJM.org). 10,23,25
Mean Sac Diameter as a Criterion for Failed Pregnancy
The size of the gestational sac, measured as the mean sac diameter (the average of the sagittal, transverse, and anteroposterior diameters of the sac), increases as pregnancy progresses. A number of studies have examined the cutoff value for the mean sac diameter above which an embryo is consistently visible on transvaginal ultrasonography in a normal pregnancy. Initial studies involving small numbers of patients put the cutoff value at 16 mm 33 and 17 mm, 34 leading to the widespread use of a mean sac diameter of 16 mm as a positivity criterion for diagnosing failed pregnancy when no embryo is seen. [29] [30] [31] The raw data from these early studies suggest that a 16-mm cutoff for the mean sac diameter has a specificity of 100% and a sensitivity of approximately 50%, but a systematic review of the Absence of embryo with heartbeat ≥2 wk after a scan that showed a gestational sac without a yolk sac Absence of embryo with heartbeat 7-13 days after a scan that showed a gestational sac without a yolk sac Absence of embryo with heartbeat ≥11 days after a scan that showed a gestational sac with a yolk sac Absence of embryo with heartbeat 7-10 days after a scan that showed a gestational sac with a yolk sac pregnancies. 10, 35 In addition, the inter observer variation in the measurement of the mean sac diameter is ±19%, 32 so a diameter of 21 mm (the upper limit above) as measured by one observer may be 19% greater, or 25 mm, when measured by another observer. These studies, in combination, suggest that it is prudent to use a cutoff of 25 mm (rather than 16 mm) for the mean sac diameter with no visible embryo ( Table 2 ) in diagnosing failed pregnancy ( Fig. 2B and 2C) . This would yield a specificity and positive predictive value of 100% (or as close to 100% as can be determined). When the mean sac diameter is 16 to 24 mm, the lack of an embryo is suspicious for, though not diagnostic of, failed pregnancy (Fig. S2 in the Supplementary Appendix).
Time-based Criteria for Failed Pregnancy
Not all failed pregnancies ever develop a 7-mm embryo or a 25-mm gestational sac, so it is important to have other criteria for diagnosing pregnancy failure. The most useful of such criteria involve nonvisualization of an embryo by a certain point in time. An alternative approach to predicting pregnancy failure, based on subnormal growth of the gestational sac and embryo, has been shown to be unreliable. 36 Nonvisualization of an embryo with a heartbeat by 6 weeks after the last menstrual period is suspicious for failed pregnancy, but dating of the last menstrual period (in a pregnancy conceived without medical assistance) is too unreliable for definitive diagnosis of pregnancy failure. 37 The timing of events in early pregnancy -gestational sac at 5 weeks, yolk sac at 5 1 ∕2 weeks, and embryo with heartbeat at 6 weeks -is accurate and reproducible, with a variation of about ± 1 ∕2 week 14, 15 ; this consistency explains the time-related criteria for pregnancy failure listed in Table 2 . For example, if the initial ultrasonogram shows a gestational sac with a yolk sac and a follow-up scan obtained at least 11 days later does not show an embryo with cardiac activity, the diagnosis of failed pregnancy is established ( Fig. 2D and 2E ; also see Fig. S3 in the Supplementary Appendix).
Other Suspicious Findings
Several ultrasonographic findings early in the first trimester have been reported as abnormal. These include an "empty" amnion, 38 an enlarged yolk sac, 39 and a small gestational sac. 40 Criteria for these abnormal findings are presented in Table 2 . Because none of these signs have been extensively studied, they are considered to be suspicious for, though not diagnostic of, failed pregnancy.
Di agnosing a nd Rul ing Ou t a V iable Intr auter ine Pr egnancy in a Woman with a Pregnancy of Unknown Location
The evaluation and management of a pregnancy of unknown location have received considerable attention, with various flow charts and mathematical models proposed for use in this context. 41, 42 Our intent here is not to review the broad topic of pregnancy of unknown location, but instead to focus on one important element: the role of an hCG level at a single point in time in diagnosing or ruling out a viable intrauterine pregnancy and in guiding patient-care decisions. The hCG levels in viable intrauterine pregnancies, nonviable intrauterine pregnancies, and ectopic pregnancies have considerable overlap, so a single hCG measurement does not distinguish reliably among them. 2, 4, 43 Considerable research during the past 30 years has sought to determine the discriminatory hCG level: the value above which an intrauterine gestational sac is consistently seen on ultra sonography in normal pregnancies. An early study, based on transabdominal ultrasonography, put the level at 6500 mIU per milliliter. 44 With improvements in ultrasonographic technology, including the introduction of transvaginal ultrasonography, gestational sacs became detectable earlier in pregnancy, and the reported discriminatory hCG level was brought down to 1000 to 2000 mIU per milliliter. [45] [46] [47] As with the crown-rump length and mean sac diameter, however, more recent research has shown that previously accepted values for the discriminatory hCG level are not as reliable for ruling out a viable pregnancy as originally thought.
One reason for the lower reliability of the discriminatory hCG level today than was reported in the past may be the fact that multiple gestations, which are associated with higher hCG levels at a given stage of pregnancy than are singleton gestations, are more common now than they were 20 to 30 years ago. Failure of the discriminatory hCG level to rule out a viable intrauterine pregnancy, however, has been seen in singleton as well as multiple gestations. Several studies have documented cases in which an embryo with cardiac activity was seen on follow-up ultrasonography after initial ultrasonography showed no gestational sac with an hCG level above 2000 mIU per milliliter 12, 48, 49 and even above 3000 mIU per milliliter. 12, 48 In a woman with a pregnancy of unknown location whose hCG level is more than 2000 mIU per milliliter, the most likely diagnosis is a nonviable intrauterine pregnancy, occurring approximately twice as often as ectopic pregnancy. 50 Ectopic pregnancy, in turn, occurs approximately 19 times as often as a viable intrauterine pregnancy when the hCG level is 2000 to 3000 mIU per milliliter and the uterus is empty, and 70 times as often as a viable intrauterine pregnancy when the hCG level is more than 3000 mIU per milliliter with an empty uterus. (These latter estimates are based on data from one institution assessing ectopic pregnancies 19 and viable intrauterine preg nancies 12 in relation to hCG levels in women with an empty uterus.)
On the basis of these values, among women with a pregnancy of unknown location and hCG levels of 2000 to 3000 mIU per milli liter, there will be 19 ectopic pregnancies and 38 nonviable intrauterine pregnancies for each viable intrauterine pregnancy. Thus, the like lihood of a viable intrauterine pregnancy for such women is [1 ÷ (1 + 19 + 38) ], or approximately 2%. If we use the same reasoning for women with a preg-nancy of unknown location and hCG levels of more than 3000 mIU per milliliter, the likelihood of a viable intrauterine pregnancy is [1 ÷ (1 + 70 + 140)], or approximately 0.5%.
We recognize that these estimates of the likelihood of a viable intrauterine pregnancy in a woman with a pregnancy of unknown location whose hCG level is 2000 mIU per milliliter or higher are not highly precise, given the limitations of the available data, but there are a number of reasons why presumptive treatment for ectopic pregnancy with the use of methotrexate or other pharmacologic or surgical means is inappropriate if the woman is hemodynamically stable. First, as noted above, there is a chance of harming a viable intrauterine pregnancy, especially if the hCG level is 2000 to 3000 mIU per milliliter. Second, the most likely diagnosis is nonviable intrauterine pregnancy (i.e., failed pregnancy), 50 and methotrexate is not an appropriate treatment for a woman with this diagnosis. Third, there is limited risk in taking a few extra days to make a definitive diagnosis in a woman with a pregnancy of unknown location who has no signs or symptoms of rupture and no ultrasonographic evidence of ectopic pregnancy. Fourth, the progression of hCG values over a period of 48 hours provides valuable information for diagnostic and therapeutic decision making. 4, 51 Thus, it is generally appropriate to do additional testing before undertaking treatment for ectopic pregnancy in a hemodynamically stable patient (Table 3) . 2, 43, 52 
Finding Key Points
No intrauterine fluid collection and normal (or nearnormal) adnexa on ultrasonography † A single measurement of hCG, regardless of its value, does not reliably distinguish between ectopic and intrauterine pregnancy (viable or nonviable). If a single hCG measurement is <3000 mIU/ml, presumptive treatment for ectopic pregnancy with the use of methotrexate or other pharmacologic or surgical means should not be undertaken, in order to avoid the risk of interrupting a via ble intrauterine pregnancy. If a single hCG measurement is ≥3000 mIU/ml, a viable intrauterine pregnancy is possible but unlikely. However, the most likely diagnosis is a nonviable intrauter ine pregnancy, so it is generally appropriate to obtain at least one followup hCG measurement and followup ultrasonogram before undertaking treatment for ec topic pregnancy.
Ultrasonography not yet performed Women with ectopic pregnancies have highly variable hCG levels, often less than 1000 mIU per milliliter, 43, 53, 54 and the hCG level does not predict the likelihood of ectopic pregnancy rupture. 55 That is, a single hCG value, even if low, does not rule out a potentially life-threatening ruptured ectopic pregnancy. Hence, ultrasonography is indicated in any woman with a positive pregnancy test who is clinically suspected of having an ectopic pregnancy.
C onclusions
A false positive diagnosis of nonviable pregnancy early in the first trimester -incorrectly diagnosing pregnancy failure in a woman with an intrauterine gestational sac or ruling out viable intrauterine gestation in a woman with a pregnancy of unknown location -can prompt interventions that damage a pregnancy that might have had a normal outcome. Recent research has shown the need to adopt more stringent criteria for the diagnosis of nonviability in order to minimize or avoid false positive test results. The guidelines presented here, if promulgated widely to practitioners in the vari-ous specialties involved in the diagnosis and management of problems in early pregnancy, would improve patient care and reduce the risk of inadvertent harm to potentially normal pregnancies.
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